Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. - Institut Pasteur Access content directly
Journal Articles European Urology Year : 2017

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Abstract

Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also preventing progression and reducing deaths. However, response rates to BCG vary widely and are dependent on a multitude of factors.

Domains

Immunology
No file

Dates and versions

pasteur-01659421 , version 1 (08-12-2017)

Identifiers

Cite

Ashish Kamat, Roger Li, Michael A O'Donnell, Peter C Black, Morgan Rouprêt, et al.. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.. European Urology, 2017, ⟨10.1016/j.eururo.2017.10.003⟩. ⟨pasteur-01659421⟩
53 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More